Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours
- 19 December 2002
- journal article
- Published by Elsevier in Neuropharmacology
- Vol. 43 (7) , 1110-1118
- https://doi.org/10.1016/s0028-3908(02)00216-2
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Effect of Long‐Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In VivoJournal of Neurochemistry, 1996
- Influence of Selective Inhibition of Monoamine Oxidase A or B on Striatal Metabolism of l‐DOPA in Hemiparkinsonian RatsJournal of Neurochemistry, 1995
- Histochemical localisation of monoamine oxidase A and B in rat brainJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1988
- Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐DeprenylJournal of Neurochemistry, 1986
- The deamination of dopamine by human brain monoamine oxidaseNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1983
- IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASEThe Lancet, 1977
- Relations Between the Degree of Monoamine Oxidase Inhibition and Some Psychopharmacological Responses to Monoamine Oxidase Inhibitors in RatsPublished by Wiley ,1976
- The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenilJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1975
- Regulation of Norepinephrine BiosynthesisAnnual Review of Pharmacology, 1970
- REGIONAL STUDIES OF CATECHOLAMINES IN THE RAT BRAIN‐IJournal of Neurochemistry, 1966